NKTR Share Price Performance
US$54.28
37.93 (231.99%)
42.2% undervalued intrinsic discount
US$93.86
Fair Value
Price US$54.28
AnalystConsensusTarget US$93.86
AnalystHighTarget US$120.00
Fair ValueUS$93.86
Share Pricen/a
Nektar Therapeutics Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
NKTR Community Narratives
AN
Fair Value US$93.86 42.2% undervalued intrinsic discount
NKTR: Upcoming Phase 2b Data Readouts Will Drive Renewed Upside Momentum
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
Fair Value US$120 54.8% undervalued intrinsic discount
Immunotherapy Advances Will Serve Aging Demand Yet Face Regulatory Hurdles
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
NKTR: Upcoming Phase 2b Data Readouts Will Drive Renewed Upside Momentum
Key Takeaways Advancing innovative therapies like REZPEG in large, underserved markets could drive substantial revenue growth and improve long-term financial performance. Strong cash reserves and accelerated regulatory paths enable operational stability, support pipeline expansion, and reduce near-term financial risks.Read more
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
US$93.86
42.2% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-11.26% p.a.
Profit Margin
20.88%
Future PE
301.81x
Share price in 2028
US$110.6
Immunotherapy Advances Will Serve Aging Demand Yet Face Regulatory Hurdles
Key Takeaways REZPEG is positioned to become a market leader in dermatology due to strong clinical data, expedited approval pathways, and potential broad patient reach. Nektar's solid financials and innovative technology platform offer undervalued growth potential, diversification, and appeal for strategic partnerships or acquisitions.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$120
54.8% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
-9.64% p.a.
Profit Margin
23.22%
Future PE
261.71x
Share price in 2028
US$144.21
Recently Updated Narratives
AN
NKTR: Upcoming Phase 2b Data Readouts Will Drive Renewed Upside Momentum
Fair Value: US$93.86 42.2% undervalued intrinsic discount
10 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Immunotherapy Advances Will Serve Aging Demand Yet Face Regulatory Hurdles
Fair Value: US$120 54.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nektar Therapeutics Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -5.94
- 87.26%
- -192.87%
- 88.3%
About NKTR
- Founded
- 1990
- Employees
- 61
- CEO
- WebsiteView website
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
